Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR plus breast cancer: A secondary analysis of the SOFT trial.

被引：0
|
作者：
Brown, Lauren Claire
Luen, Stephen James
Molania, Ramyar
Caramia, Franco
Savas, Peter
VanGeelen, Courtney
Chic, Nuria
Fleming, Gini F.
Kammler, Rosita
Colleoni, Marco
Viale, Giuseppe
Speed, Terence Paul
Regan, Meredith M.
Francis, Prudence A.
Loi, Sherene
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Chicago, Chicago, IL USA
[3] Int Breast Canc Study Grp, Bern, Switzerland
[4] European Inst Oncol, Milan, Italy
[5] Univ Milan, European Inst Oncol, Milan, Italy
[6] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[7] Dana Farber Canc Inst, Boston, MA USA
[8] Int Breast Canc Study Grp, Boston, MA USA
[9] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
504
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Outcomes of Breast-Conserving Surgery Plus Radiation vs Mastectomy for All Subtypes of Early-Stage Breast Cancer: Analysis of More Than 200,000 Women
    Chu, Quyen D.
    Hsieh, Mei-Chin
    Yi, Yong
    Lyons, John M.
    Wu, Xiao-Cheng
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2022, 234 (04) : 450 - 464
  • [32] Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): Update of the SOFT trial
    Fleming, Gini
    Francis, Prudence A.
    Lang, Istvan
    Ciruelos, Eva M.
    Bellet, Meritxell
    Bonnefoi, Herve R.
    Climent, Miguel A.
    Pavesi, Lorenzo
    Burstein, Harold J.
    Martino, Silvana
    Davidson, Nancy E.
    Geyer, Charles E., Jr.
    Walley, Babara A.
    Coleman, Robert E.
    Kerbrat, Pierre
    Buchholz, Stefan
    Ingle, James N.
    Rabaglio-Poretti, Manuela
    Colleoni, Marco
    Regan, Meredith M.
    CANCER RESEARCH, 2018, 78 (04)
  • [33] Trends in use of ovarian suppression (OS) for premenopausal patients with early-stage hormone positive breast cancer and Intermediate Risk (IR) Oncotype Recurrence Scores (RS) from 2006-2020: A retrospective database analysis.
    Hovstadius, Sara Malin
    Zimmerman, Brittney Shulman
    Berwick, Shana
    Blanter, Julia
    Berger, Natalie F.
    Moshier, Erin
    Berkalieva, Asem
    Jaffer, Shabnam
    Cascetta, Krystal Pauline
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
    Gnant, Michael
    Mlineritsch, Brigitte
    Stoeger, Herbert
    Luschin-Ebengreuth, Gero
    Heck, Dietmar
    Menzel, Christian
    Jakesz, Raimund
    Seifert, Michael
    Hubalek, Michael
    Pristauz, Gunda
    Bauernhofer, Thomas
    Eidtmann, Holger
    Eiermann, Wolfgang
    Steger, Guenther
    Kwasny, Werner
    Dubsky, Peter
    Hochreiner, Gerhard
    Forsthuber, Ernst-Pius
    Fesl, Christian
    Greil, Richard
    LANCET ONCOLOGY, 2011, 12 (07): : 631 - 641
  • [35] Immune response following neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: A correlative analysis of the SOLTI-1402 CORALLEEN phase 2 randomized trial
    Chic, Nuria
    Gonzalez Farre, Blanca
    Pare, Laia
    Pascual, Tomas
    Saura, Cristina
    Hernando, Cristina
    Munoz, Montserrat
    Fernandez, Pedro
    Galvan, Patricia
    Gonzalez Farre, Xavier
    Oliveira, Mafalda
    Gil, Miguel Gil
    Celiz, Pamela
    Ciruelos, Eva
    Villagrasa, Patricia
    Gavila, Joaquin
    Prat, Aleix
    CANCER RESEARCH, 2020, 80 (04)
  • [36] Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
    Miguel Martin
    Jan C. Brase
    Amparo Ruiz
    Aleix Prat
    Ralf Kronenwett
    Lourdes Calvo
    Christoph Petry
    Philip S. Bernard
    Manuel Ruiz-Borrego
    Karsten E. Weber
    César A. Rodriguez
    Isabel M. Alvarez
    Miguel A. Segui
    Charles M. Perou
    Maribel Casas
    Eva Carrasco
    Rosalía Caballero
    Alvaro Rodriguez-Lescure
    Breast Cancer Research and Treatment, 2016, 156 : 81 - 89
  • [37] Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer A Secondary Analysis of the GeparOcto Randomized Clinical Trial
    Pohl-Rescigno, Esther
    Hauke, Jan
    Loibl, Sibylle
    Moebus, Volker
    Denkert, Carsten
    Fasching, Peter A.
    Kayali, Mohamad
    Ernst, Corinna
    Weber-Lassalle, Nana
    Hanusch, Claus
    Tesch, Hans
    Mueller, Volkmar
    Altmueller, Janine
    Thiele, Holger
    Untch, Michael
    Luebbe, Kristina
    Nuernberg, Peter
    Rhiem, Kerstin
    Furlanetto, Jenny
    Lederer, Bianca
    Jackisch, Christian
    Nekljudova, Valentina
    Schmutzler, Rita K.
    Schneeweiss, Andreas
    Hahnen, Eric
    JAMA ONCOLOGY, 2020, 6 (05) : 744 - 748
  • [38] Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
    Martin, Miguel
    Brase, Jan C.
    Ruiz, Amparo
    Prat, Aleix
    Kronenwett, Ralf
    Calvo, Lourdes
    Petry, Christoph
    Bernard, Philip S.
    Ruiz-Borrego, Manuel
    Weber, Karsten E.
    Rodriguez, Cesar A.
    Alvarez, Isabel M.
    Segui, Miguel A.
    Perou, Charles M.
    Casas, Maribel
    Carrasco, Eva
    Caballero, Rosalia
    Rodriguez-Lescure, Alvaro
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (01) : 81 - 89
  • [39] DENOSUMAB VERSUS PLACEBO AS ADJUVANT TREATMENT FOR WOMEN WITH EARLY-STAGE BREAST CANCER AT HIGH RISK OF DISEASE RECURRENCE (D-CARE): AN IN PROGRESS, PHASE 3 CLINICAL TRIAL
    Coleman, R. E.
    Barrios, C.
    Bell, R.
    Finkelstein, D. M.
    Iwata, H.
    Martin, M.
    Braun, A.
    Ke, C.
    Maniar, T.
    Goss, P. E.
    ANNALS OF ONCOLOGY, 2012, 23 : 115 - 115
  • [40] Prediction of 10yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a Danish breast cancer group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR plus ) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone
    Laenkholm, A-V
    Jensen, M-B
    Buckingham, W.
    Schaper, C.
    Knoop, A.
    Eriksen, J. O.
    Rasmussen, B. B.
    Ferree, S.
    Haffner, T.
    Kiboel, T.
    Ejlertsen, B.
    CANCER RESEARCH, 2017, 77
12345